

***Fiscal Year 2024 (FY24) Department of Defense Melanoma Research Program (MRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>**NEW for FY24** Survivorship Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524MRPSRA</p>	<p>The Principal Investigator (PI) must be an <i>independent</i> investigator at any career level.</p> <p>Individuals in a mentored position (e.g., postdoctoral fellows, clinical fellows) are <i>not</i> considered independent and are <i>not</i> eligible to be named as PI.</p> <p>PIs must be employed by or affiliated with an eligible organization, <i>which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</i></p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Supports a broad range of innovative and impactful survivorship research that has the intended outcome of improving the health and well-being of melanoma survivors (active- or post-treatment), their families and/or their caregivers. • Areas of survivorship research of interest to the MRP include, but are not limited to: <ul style="list-style-type: none"> ○ Preservation of function and symptom management throughout treatment and beyond ○ Psychological and social impacts of a melanoma diagnosis and treatment ○ Treatment outcomes ○ Health care delivery and disparity • The research team is <i>required</i> to collaborate with the melanoma consumer community (e.g., melanoma survivors, caregivers) to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a community advisory board. • <i>Clinical trials <u>are</u> allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET</p> <p>Application: August 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524MRPIA</p>	<p>The PI must be at or above the level of Postdoctoral Fellow or equivalent.</p> <p>PIs must be employed by or affiliated with an eligible organization, <i>which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</i></p>	<ul style="list-style-type: none"> • **UPDATED FOR FY24** A letter of intent is required; <u>an invitation to submit a full application is NOT required.</u> • Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond incremental advancements or the next logical step in a line of research already established by the PI. • Emphasis on innovation and potential impact. • Must address at least one of the FY24 MRP Focus Areas. • Preliminary data are discouraged. Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative intent of this award. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$400,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET</p> <p>Application: August 26, 2024 11:59 p.m. ET</p>
<p>Melanoma Academy Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524MRPMASA</p>	<p>The PI (i.e., Scholar) must be within 7 years of their first faculty-level appointment as of the full application submission deadline.</p> <p>A letter attesting to eligibility is required.</p> <p>PIs must be employed by or affiliated with an eligible organization, <i>which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</i></p>	<ul style="list-style-type: none"> • A letter of intent is required; an invitation to submit a full application is not required. • Supports the addition of new Scholars to the unique, interactive virtual Melanoma Academy that provides intensive mentoring, national networking, collaborations and a peer group for early-career melanoma investigators. • Requires a Career Guide who is an experienced melanoma researcher with a history of obtaining melanoma research funding. • The Career Guide is not required to be at the same institution as the Scholar. • The Career Guide must be committed to participating in the Melanoma Academy, including serving in advisory roles as requested by Academy Leadership. • Must address at least one of the FY24 MRP Focus Areas. • Preliminary data are not required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$550,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET</p> <p>Application: August 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Team Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524MRPTSA</p>	<p>At least two and up to three PIs must partner in one multidisciplinary research study.</p> <p>PIs must be <i>independent</i> investigators at any career level.</p> <p>Individuals in a mentored position (e.g., postdoctoral fellows, clinical fellows) are <i>not</i> considered independent and <i>are not</i> eligible to be named as either Initiating or Partnering PI.</p> <p>Inclusion of at least one military, U.S. Department of Veterans Affairs or Early-Career Investigator is encouraged.</p> <p>PIs must be employed by or affiliated with an eligible organization, <i>which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</i></p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts. • Each PI should have equal intellectual input into the design <i>and</i> execution of the project. • Intended to fund a broad range of studies including, but not limited to: <ul style="list-style-type: none"> ◦ <i>Translational research</i> that leverages clinical samples from established biobanks, established biorepositories and/or ongoing or completed clinical trials ◦ <i>Data science research</i> involving the analysis of large and/or complex melanoma datasets ◦ Research that used <i>bioengineering approaches</i> to develop tools that assist in the detection, diagnosis, prognosis and/or treatment of melanoma ◦ Research seeking to better understand and/or reduce <i>inequities and disparities</i> that impact a person, their family and/or their caregiver’s ability to prevent, detect, manage and survive melanoma • Emphasis on multidisciplinary research and impact. • The research team is encouraged, but not required, to collaborate with the melanoma consumer community (e.g., melanoma survivors [active- or post-treatment], caregivers) to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a community advisory board. • <i>Must</i> address at least one of the FY24 MRP Focus Areas. • <i>Preliminary data are required.</i> Preliminary data do not have to be derived from melanoma studies. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET)</p> <p>Application: August 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Focused Program Award – Rare Melanomas</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524MRPFARM</p>	<p>The PI must be an independent investigator at or above the level of Associate Professor (or equivalent).</p> <p>The Project Leader(s) for the complementary research project(s) must be an independent investigator(s) at or above the level of Assistant Professor (or equivalent).</p> <p>PIs must be employed by or affiliated with an eligible organization, <i>which includes foreign or domestic organizations, for-profit and nonprofit organizations and public entities.</i></p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment and quality of life) and <i>must</i> address a critical unmet need relevant to <i>rare melanomas</i> (uveal, acral, mucosal, pediatric, etc.). • Supports a multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to <i>rare melanomas</i>. • Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials. • The research team assembled by the PI should be highly qualified and multidisciplinary, with an identified Project Leader(s) for the complementary and synergistic research project(s). • The research team is encouraged, but not required, to collaborate with the rare melanoma consumer community to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a rare melanoma consumer community advisory board. • <i>Clinical trials <u>are</u> allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): July 29, 2024 5:00 p.m. ET</p> <p>Application: August 26, 2024 11:59 p.m. ET</p>